Dr David Moore PhD

Institute of Applied Health Research
Senior Lecturer

Contact details

+44 (0)121 414 7449
+44 (0)121 414 7878
Public Health, Epidemiology and Biostatistics
Institute of Applied Health Research
College of Medical and Dental Sciences
University of Birmingham
Birmingham, B15 2TT

Dr Moore is responsible for..

  • leading teams undertaking systematic reviews and project managing the production of systematic reviews
  • appraising the strengths and weaknesses of systematic reviews undertaken by other reviewers
  • improving the incorporation of research evidence in population level health care decisions
  • teaching at both undergraduate and postgraduate level and academic tutor to post graduate students


David also has a background in primary research in ophthalmology through which he obtained a PhD. He has previously worked at the Institute of Ophthalmology (London), the United Medical and Dental Schools of Guy's and St. Thomas' Hospitals and the University of Auckland, New Zealan


Teaching Programmes


  • Health Technology Assessment
  • Systematic Reviews
  • Evidence Synthesis.


Connock M; Hyde C, Moore D. Cautions regarding the fitting and interpretation of survival curves: examples from NICE Single Technology Appraisals of drugs for cancer. PharmacoEconomics: 2011; 29(10):827-837

Malottki K, Barton P, Tsourapas A, Uthman A, Liu Z, Routh R, Connock R, Jobanputra P, Moore D, Fry-Smith A, Chen Y. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor: a systematic review and economic evaluation. Health Technology Assessment: 2011; 15(14)

Connock M, Tubeuf S,  Malottki K, Uthman A, Round J, Bayliss S, Meads C, Moore D. Certolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis. Health Technology Assessment: 2010; Vol. 14 Suppl. 2; 1-10

Connock M, Round J, Bayliss S, Tubeuf S, Greenheld W, Moore D. Sorafenib for the treatment of advanced hepatocellular carcinoma. Health Technology Assessment 2010; Vol. 14: Suppl. 1; 17-21

Meads C, Round J, Tubeuf S, Moore D, Pennant M, Bayliss S. Cetuximab for the first-line treatment of metastatic colorectal cancer Health Technology Assessment 2010;14: Suppl.1; 1-8

Chen Y-F, Jowett S, Barton P, Malottki K, Hyde C, Gibbs JSR, Pepke-Zaba J, Fry-Smith A, Roberts J, Moore D. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation. Health Technology Assessment 2009; 13(49)

Moore D, Adi Y, Connock M, Bayliss S. Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation. BMC Endocrine Disorders 2009, 9:20 doi:10.1186/1472-6823-9-20

Moore D, Aveyard P, Connock M, Wang D, Fry-Smith A, Barton P. Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis. BMJ 2009;338:b1024